Atlas Trials

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Clinical trial NCT02716805 · TERMINATED

Trial details

NCT number
NCT02716805
Sponsor
Ludwig Institute for Cancer Research
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2016-12-13
Primary completion
2018-02-16
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.